Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01251640 · ClinicalTrials.gov registry record · Phase 1
Combination With Gemcitabine in Advanced Pancreatic Cancer
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT01251640 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 90 participants.
The verdict
NCT01251640, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
Open-label, uncontrolled, Phase I/II study to evaluate safety and efficacy of BAY86-9766 plus gemcitabine in locally advanced, unresectable or metastatic pancreatic cancer. Phase I: Dose escalation study investigating 20, 30 and 50 mg BAY86-9766 plus gemcitabine (1000mg/m2); determination of maximum tolerated dose and recommended phase 2 dose. Phase II: Determination of response (RECIST 1.1; primary endpoint). Secondary endpoints: response duration, disease control rate, time to progression, progression-free survival, overall survival, safety and tolerability. Tumor assessments at Screening and than every 8 weeks.; Safety evaluations at Screening and weekly throughout the study; Safety follow-up visit 30 days after the last dose of study treatment; Survival follow up monthly for up to 8 month after LPFV.
Interventions
- DRUG BAY86-9766+Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2011-01-01 |
| Est. Completion | 2013-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01251640
The ClinicalTrials.gov registry entry for NCT01251640 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BAY86-9766+Gemcitabine is the first listed.
NCT01251640 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01251640 about?
NCT01251640 is a clinical study titled "Combination With Gemcitabine in Advanced Pancreatic Cancer". Open-label, uncontrolled, Phase I/II study to evaluate safety and efficacy of BAY86-9766 plus gemcitabine in locally advanced, unresectable or metastatic pancreatic cancer. Phase I: Dose escalation study investigating 20, 30 and 50 mg BAY86-9766 plus gemcitabine (1000mg/m2); determination of maximu...
What is the current status of trial NCT01251640?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2011-01-01. Estimated completion is 2013-08-01.
What interventions are being tested in trial NCT01251640?
The interventions under investigation include: BAY86-9766+Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT01251640?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.